Linezolid Fresenius Kabi

Linezolid, the active ingredient in Linezolid Fresenius Kabi, is an oxazolidinone presented as an intravenous solution for intravenous use. It treats complicated skin and soft tissue infections, community‑acquired and nosocomial pneumonia, and infections caused by MRSA or VRE in adult patients.

GNH USA supplies Linezolid Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Linezolid is an oxazolidinone antibacterial used to treat serious Gram‑positive infections.

- Complicated skin and soft tissue infections: effective against susceptible Gram‑positive bacteria, including MRSA, reducing infection severity. - Community‑acquired and nosocomial pneumonia: provides bacteriostatic activity against the causative pathogens, improving respiratory outcomes. - Infections caused by vancomycin‑resistant Enterococcus (VRE): offers an alternative treatment option for resistant Gram‑positive infections.

Linezolid may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset occurring in many patients. - Diarrhea: loose stools that may be self‑limiting. - Headache: transient cranial discomfort. - Thrombocytopenia: reduction in platelet count, usually mild.

Serious or Rare Side Effects: - Myelosuppression: significant decrease in bone‑marrow activity leading to anemia or neutropenia. - Peripheral neuropathy: nerve damage causing tingling or numbness, potentially irreversible. - Lactic acidosis: accumulation of lactate causing metabolic acidosis, a life‑threatening condition.

When using Linezolid, clinicians should observe several safety considerations to minimize risks.

- Monitor blood counts: regular CBC testing to detect thrombocytopenia or anemia. - Assess renal and hepatic function: adjust therapy if significant impairment is present. - Watch for serotonin syndrome: avoid concomitant serotonergic agents. - Evaluate for peripheral neuropathy: discontinue if symptoms develop. - Use caution in pregnancy: limited data; risk‑benefit assessment required. - Store at ambient temperature: keep below 25°C, protect from moisture and light in original packaging.

Linezolid can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic drugs: risk of serotonin syndrome. - Monoamine oxidase inhibitors (MAOIs): increased risk of hypertensive crisis. - Rifampicin: reduces linezolid plasma concentrations, compromising effectiveness.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Ethanol: potential for disulfiram‑like reaction, causing flushing and nausea. - Anticonvulsants (e.g., carbamazepine): may lower linezolid levels, necessitating therapeutic monitoring.